Vicriviroc

Articles on Vicriviroc

Merck Decides to Stop Development of Vicriviroc for Treatment of HIV
7/16/2010

Vicriviroc Fails to Beat Stiff Competition, Merck Will Not File for Treatment-experienced Approval
2/19/2010

Experimental CCR5 Antagonist Vicriviroc Appears Safe and Well Tolerated in HIV/HCV Coinfected Patients
1/12/2010

CCR5 Antagonist Vicriviroc Demonstrates Greater Efficacy in Patients Identified Using More Sensitive CCR5 Tropism Test
1/12/2010

CCR5 Antagonist Vicriviroc Demonstrates Long-Term Safety and Efficacy at 96 Weeks
9/14/2009

Assessment of Pharmacokinetic and Safety Interactions Between Vicriviroc and CYP3A4 Substrates, Inhibitors, and Inducers
9/14/2009

Clonal Analysis of the gp120 V3 Loop from Clinical Isolates Displaying Phenotypic Resistance to Vicriviroc
9/14/2009

Vicriviroc Long-term Safety and Efficacy: 96-Week Results from the VICTOR-E1 Study
9/14/2009

Comparison of Trofile® and ViroTectTropism Assays in Treatment-Experienced Subjects
2/10/09.

Rapamycin Enhances Anti-HIV Activity of Experimental CCR5 Antagonist Vicriviroc
1/16/09

Long-term Safety of Vicriviroc
11/05/2008

Low Doses of CCR5 Antagonist Vicriviroc Do Not Suppress HIV as well as Efavirenz (Sustiva) in Treatment-naive Patients; New Study Underway
10/14/08

Schering-Plough Initiates Phase II Study with Vicriviroc in Treatment-naïve HIV-infected Patients
4/16/08

CCR5 Antagonist Vicriviroc Shows Continued Benefits and Good Tolerability at 48 Weeks: VICTOR-E1 Trial
2/05/08

Vicriviroc, a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral Replication in Treatment-Experienced Adults: VICTOR-E1 48-week Results.
2/10/08

Vicriviroc, a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral Replication in Treatment-Experienced Adults: VICTOR-E1 48-week Results
2/05/08

Effect of Virus Concentration on in vitro Measurement of Phenotypic Resistance to the CCR5 Antagonist Vicriviroc.
2/05/08